Yacub v. Sandoz Pharmaceuticals Corp.

101 F. Supp. 2d 852, 1998 U.S. Dist. LEXIS 22381, 1998 WL 1574650
CourtDistrict Court, S.D. Ohio
DecidedDecember 22, 1998
DocketC-3-96-297
StatusPublished
Cited by4 cases

This text of 101 F. Supp. 2d 852 (Yacub v. Sandoz Pharmaceuticals Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yacub v. Sandoz Pharmaceuticals Corp., 101 F. Supp. 2d 852, 1998 U.S. Dist. LEXIS 22381, 1998 WL 1574650 (S.D. Ohio 1998).

Opinion

DECISION AND ENTRY VACATING MARCH 27, 1998, DECISION AND ENTRY (DOC. #39) IN PART; DEFENDANT SANDOZ PHARMACEUTICALS CORPORATION’S MOTION FOR SUMMARY JUDGMENT (DOC. # 20) OVERRULED; TRIAL DATE ON ALL ISSUES SET FOR OCTOBER 4,1999.

RICE, Chief Judge.

This litigation arises out of Cheryl Ya-cub’s death, which occurred on February 17, 1991. The Plaintiff, who is her surviving spouse and the administrator of her estate, brings this action on behalf of the estate and Mariam Yacub, his minor child. The Plaintiff contends that the death of Cheryl Yacub (hereinafter “Cheryl Yacub” or “Yacub”) was caused by her taking Par-lodel, a drug manufactured by Defendant Sandoz Pharmaceuticals Corporation (“Sandoz”). 1 His Amended Complaint sets forth, in effect, two claims for relief: a survivorship claim on behalf of the estate, and a loss of consortium claim on behalf of Mariam Yacub. 2

In a March 27, 1998, Decision and Entry (Doc. # 39), the Court sustained in part and overruled in part a Motion for Summary Judgment (Doc. # 20) filed by San-doz. The Court sustained the Motion to the extent it sought summary judgment on the Plaintiffs survivorship claim, which the Court found time-barred by the statute of limitations, but overruled the Motion to the extent it sought summary judgment on the loss of consortium claim. The Court also noted that it would file an Expanded Opinion, with reasoning and citation to au *855 thority, supporting its decision concerning the survivorship claim. 3 Upon further reflection, however, the Court concludes that the Plaintiffs survivorship claim is not barred by the applicable statute of limitations. Consequently, for the following reasons, the Court hereby vacates its March 27,1998, decision and entry to the extent it granted Sandoz summary judgment on the Plaintiffs survivorship claim, and overrules Sandoz’ Motion on the issue.

I. Factual and Procedural Background

Cheryl Yacub discovered that she was pregnant in May, 1990. (Yacub depo. at 28). Prior to her pregnancy, Yacub had no history of serious health problems and no history of headaches. (Id. at 23). Her pregnancy was relatively uneventful, and she experienced no problems other than a bladder infection, which her doctor treated with antibiotics. (Id. at 28). Yacub gave birth to Mariam Yacub by caesarian section on February 5, 1991, at the Timken Mercy Medical Center. (Id. at 30). She progressed normally following the delivery and had no complaints of headaches while at the hospital. (Id. at 32). Yacub was discharged on February 8, 1991, and prescribed Parlodel to suppress postpartum lactation. (Id. at 40, 45).

Yacub took the medication as directed following her release from the hospital. (Id. at 46). On February 11, 1991, she first complained to the Plaintiff about having a headache that radiated from behind her ear. (Id. at 47). She explained that the pain was unlike any headache she ever had experienced before. (Id. at Exh. 1, p. 3). The following day, the Plaintiff went with Yacub to the Timken Mercy Medical Center’s Emergency Room. (Yacub depo. at 51-52). The Yacubs told the emergency room doctor that Cheryl Yacub was taking Parlodel and Tylenol. (Id. at 53). The doctor took a CAT scan, which was negative, and prescribed Darvocet for the headaches. (Id. at 54).

After returning home, Yacub continued experiencing headaches, which became even worse. She also experienced a visual disturbance “like a bright light, [like] Christmas lights.” (Id. at 59). At that time, Cheryl Yacub wondered whether her headaches were being caused by contamination of her epidural. (Id. at 60). The headaches continued through February 16, 1991, and she continued taking her regular doses of Parlodel. (Id. at 61-63, 67). Ya-cub “was in such a throbbing pain” that she had difficulty moving. (Id. at 69). She spoke with Dr. Jagadeesan, her physician, on the telephone, and the doctor told her to make an appointment with a neurologist the following day. (Id. at 71). Approximately one hour later, Yacub began convulsing while making baby formula and suffered a seizure. (Id. at 72). She was transported to the Timken Mercy emergency room and later placed in the intensive care unit. (Id. at 73).

One of the doctors at the medical center mentioned that Yacub’s illness might be due to meningitis or venus thrombosis. (Id. at 75 and Exh. 1, p. 6). The Plaintiff also asked whether Yacub’s physical problems might be due to a spinal leak from her epidural, but a doctor ruled that possibility out based upon her symptoms. (Id. at Exh. 1, p. 6). The doctor did a spinal tap to check for meningitis, but doubted its presence based upon the color of her spinal fluid. (Id.). The doctor also explained that Yacub’s condition was too poor to administer a dye test for venus thrombosis. (Id.) Additionally, he stated that the *856 only treatment for thrombosis was to provide Yacub with plenty of fluids, which already was being done. Cheryl Yacub died later that evening after her temperature rose to 108 degrees and ■ her heart stopped functioning. (Id.).

Yacub never read any literature about Parlodel while taking the medication. (Ya-cub affidavit, Doc. #21 at Exh. B, ¶2). Furthermore, neither Yacub nor the Plaintiff asked her doctors whether the headaches could have been caused by Parlodel, and none of the doctors at Timken Mercy ever told the Plaintiff what caused Yacub’s death. (Id. at ¶¶ 3-7; Yacub depo. at 167, 174).

The Plaintiff subsequently consulted three attorneys later in 1991 concerning his wife’s death. (Id. at 93). He terminated his relationship with the first attorney, after counsel requested an additional $6,000 to conduct medical research. (Id. at 97). The Plaintiffs relationship with the other two attorneys terminated after they informed him he did not have a meritorious case. As a result of his consultation with the attorneys, however, the Plaintiff received a report from Medview, a medical reporting service that had reviewed his wife’s medical records. (Id. at 83, 85, 170-171). The Plaintiff reviewed the report in November, 1991. It noted that the apparent cause of Yacub’s health problems, and ultimate death, was thrombosis. (Yacub affidavit at Exh. 2, p. 5) The report also identified three specific “risk factors” as possibly causing Yacub’s thrombosis: her pregnancy, coagulase positive staph infection, and her use of Parlo-del. (Id.). The report included an analysis explaining the possible connection each of these factors might have had to his wife’s death. (Id. at p. 2-4). With respect to Parlodel, the report advised the Plaintiff that a number of other Parlodel users had experienced physical problems like his wife’s. (Id. at p. 2).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Carpenter Co. v. BASF SE
683 F. Supp. 2d 1214 (D. Kansas, 2010)
In Re Urethane Antitrust Litigation
683 F. Supp. 2d 1214 (D. Kansas, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
101 F. Supp. 2d 852, 1998 U.S. Dist. LEXIS 22381, 1998 WL 1574650, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yacub-v-sandoz-pharmaceuticals-corp-ohsd-1998.